A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.

Trial Details

NCT ID

NCT06844357

Phase

PHASE2 / PHASE3

Sponsor

Zhejiang Raygene Pharmaceuticals Co., Ltd

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

tirapazamine
Transarterial Embolization (TAE)
TACE

Locations (sample)

Nanjing, Jiangsu, China|32.06167,118.77778
Lishui, Zhejiang, China|28.46042,119.91029

Key Eligibility Criteria

Patients diagnosed with primary hepatocellular carcinoma according to AASLD criteria.
No evidence of extrahepatic metastasis, regional lymph node involvement, or vascular tumor thrombus.
Patients must be eligible for TAE or TACE treatment.
Child-Pugh score ≤ 7.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →